Name (Synonyms) | Correlation |
---|
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
SARS-CoV2-specific T cell lines have been made at Baylor College of Medicine from healthy donors who have made a full recovery from COVID19. The cells are then frozen.These cells will be used to treat patients with confirmed SARS-CoV-2 infection who are at high risk of requiring mechanical ventilation.
Description: Primary end point: Treatment-related adverse events (tAE), including GVHD, worsening CRS, and any other treatment-related toxicities by day 14 post-infusion.
Measure: Safety of administering partially HLA-matched SARS-CoVSTs to hospitalized COVID19 patients with high risk of progression to mechanical ventilation. Time: 14 days post infusionDescription: Secondary endpoint: Improvement on the WHO Ordinal Scale by day 14 post-infusion.
Measure: Efficacy of anti-COVID19 of administering banked partially HLA-matched SARS-CoVSTs to hospitalized COVID19 patients. Time: 14 days post infusion